- Home
- THC vs GMAB Comparison
THC vs GMAB Comparison
Compare THC & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THC
- GMAB
- Stock Information
- Founded
- THC 1967
- GMAB 1999
- Country
- THC United States
- GMAB Denmark
- Employees
- THC N/A
- GMAB N/A
- Industry
- THC Hospital/Nursing Management
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- THC Health Care
- GMAB Health Care
- Exchange
- THC Nasdaq
- GMAB Nasdaq
- Market Cap
- THC 11.7B
- GMAB 13.7B
- IPO Year
- THC N/A
- GMAB N/A
- Fundamental
- Price
- THC $167.86
- GMAB $21.16
- Analyst Decision
- THC Buy
- GMAB Buy
- Analyst Count
- THC 16
- GMAB 9
- Target Price
- THC $184.50
- GMAB $39.17
- AVG Volume (30 Days)
- THC 1.7M
- GMAB 1.2M
- Earning Date
- THC 07-23-2025
- GMAB 08-07-2025
- Dividend Yield
- THC N/A
- GMAB N/A
- EPS Growth
- THC N/A
- GMAB 276.80
- EPS
- THC 15.09
- GMAB 18.36
- Revenue
- THC $20,520,000,000.00
- GMAB $3,230,902,140.00
- Revenue This Year
- THC $2.22
- GMAB $747.74
- Revenue Next Year
- THC $5.01
- GMAB $14.81
- P/E Ratio
- THC $11.06
- GMAB $1.15
- Revenue Growth
- THC N/A
- GMAB 25.43
- 52 Week Low
- THC $109.82
- GMAB $17.24
- 52 Week High
- THC $174.14
- GMAB $28.56
- Technical
- Relative Strength Index (RSI)
- THC 58.77
- GMAB 45.96
- Support Level
- THC $154.33
- GMAB $22.70
- Resistance Level
- THC $170.27
- GMAB $23.13
- Average True Range (ATR)
- THC 6.25
- GMAB 0.39
- MACD
- THC -1.06
- GMAB -0.13
- Stochastic Oscillator
- THC 70.90
- GMAB 12.44
About THC Tenet Healthcare Corporation
Tenet Healthcare is a Dallas-based healthcare services organization. It operates a collection of hospitals (about 60 as of December 2023) and over 450 ambulatory surgery centers and other outpatient facilities across the U.S., primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.